Invited Speakers

Professor Oluf Borbye Pedersen
University of Copenhagen

Lecture: “Is dysbiosis of the intestinal microbiota a pathogenic mediator in common chronic disorders?”

Sunday 10th

Biographic sketch

Currently, Dr Oluf Pedersen is principal investigator at Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen (; he is Professor of Molecular Metabolism and Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen. During 2011 to 2016: co-founder and scientific director of Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen. 2007-2014 he was founder and director of Lundbeck Foundation Centre for Applied Medical Genomics in Personalised Disease Prediction, Prevention and Care ( From 1989 to 2010 he was Chief Physician and Research Director at Steno Diabetes Centre and Hagedorn Research Institute, Copenhagen, a leading European and WHO-collaborative diabetes centre. Dr. Pedersen is a Danish Health Board-authorised Specialist of Internal Medicine (1987) and Specialist of Endocrinology (1987).< Author or co-author of >700 scientific articles with 630 original papers in peer-reviewed journals including NEJM (7), Nature (7); Nature Biotechnology (2), Nature Methods (1), Nature Genetics (21), Nature Microbiology (2), Science (1), PNAS (3), Lancet (3), PLOS Genetics (7), Am J Hum Gen (4), J Clin Invest (10), Diabetes (73), Diabetologia (84); and 105 scientific reviews or textbook chapters; Web of Knowledge bibliometrics (Thomson Reuters); total citations 35, 961 ; h-index:85. Google Scholar bibliometrics: total citations 61, 022; h-index 102. Featured by Thomson Reuters in 2014 as being among the world’s most influential scientific minds (category: molecular biology & genetics).) Major innovation in clinical diabetes care (Steno-2 study), and molecular genetics and gut metagenomics of common metabolic disorders. He has received recognition as evidenced by a knighthood and 15 international and national personal awards; services as chairman or member on boards of scientific societies, biomedical councils, grant bodies and scientific journals. University supervisor for 50 research fellows who have achieved their doctor of medicine degree (Dr Med) or their PhD degree.



Professor Piet Gros
Utrecht University

Lecture: “New opportunities in structural biology using cryo-electron microscopy“

Monday 11th

Biographic sketch

Piet Gros (1962) heads the laboratory of Crystal and Structural Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University in The Netherlands. He received his MSc degree in Chemistry cum laude at the University of Groningen in 1985 and obtained his PhD degree cum laude in Protein Crystallography under the supervision of prof. Wim Hol, University of Groningen in 1990. He was post-doctoral fellow in the labs of prof. Wilfred van Gunsteren, ETH Zurich Switzerland (1990-1992), and prof. Axel Brunger, Yale University New Haven, USA (1992-1994). In 1994 he returned to The Netherlands and set up a research group in Protein Crystallography at the Utrecht University. In 2002 he became full professor in Utrecht. He was department chair of Chemistry (2007-2010), scientific director of the Bijvoet Center (2012-2016) and is currently program director of het Utrecht Life Science (2017-onwards) at the Utrecht University. Piet Gros published ca. 100 research papers, cited >20,000 times, received an ERC Advanced Grant in 2008, became a member of the Royal Academy of The Netherlands (KNAW) in 2010, was awarded the Spinoza prize 2010 by the Netherlands Organisation for Scientific Research (NWO) and was knighted in the Order of The Netherlands Lion in 2013. Piet Gros and his research group study the molecular mechanisms of recognition and regulation that underlie biological processes. His major expertise is in structural biology of large human plasma proteins and cell-surface receptors and membrane proteins. Regulation in cells and organisms is achieved by the interplay of proteins acting in concert to achieve a control over time and space. In many cases, the proteins involved are multi-domain proteins that function in large complexes. This enables a collective set of proteins to form a protein machinery that carries out elementary regulatory functions such as initiation, amplification, localization and inhibition. His research goal is to reveal the mechanisms of activation in multi-domain proteins and multi-protein complexes that underlie the recognition and regulation processes as well as to understand the integration of the separate molecular steps, which determine the outcome of a pathway. For key publications and research highlights see:

Professor Dror Mevorach

Hadassah and the Hebrew University of Jerusalem

Lecture: “What can we learn about the complement system from diseases due to congenital loss of function of membrane complement regulators?”

Tuesday 12th

Biographic sketch

Professor Dror Mevorach is a Chairman of Medicine and Directs the Rheumatology Research Center at Hadassah and the Hebrew University, and serves as the Vice-Dean for Teaching Affairs of the Hebrew University Faculty of Medicine in Jerusalem. He is the Founder and Chief Scientific and Medical Officer of Enlivex Pharmaceuticals Ltd., a cell immunotherapy company that is developing autologous and allogeneic drugs for the treatment of autoimmune and inflammatory conditions.

He was born and grew up in Jerusalem Israel and received his MD degree, Cum laude, at the Technion Faculty of Medicine (Haifa) in 1990. Following a residency in Medicine at Hadassah, he completed a 3-year fellowship at Cornell University in New York City, where he worked with Professor Keith Elkon. He published with Prof. Elkon (J Exp Med 1998) research that established the role of the complement in apoptotic cell clearance, and the role of clearance of dying cells in the pathogenesis of systemic lupus erythematosus (SLE). Upon his return to Israel, he established his lab and continued to publish research related to the role of complement in clearance of dying cells and in negative pro-inflammatory signaling of macrophages and dendritic cells (J Exp Med 2002, Nature Immunol 2005, Blood 2006, Circulation 2009, Euro J immunol 2010, J immunol 2010, PlosOne 2012-15, Immunity 2015).

In the last 5 years, he began to decipher the genetic basis and pathogenesis of monogenic autoimmune and autoinflammatory diseases and showed the molecular pathogenesis of 4 novel diseases related to innate immunity. Additional conditions are currently under investigation in his lab. He is a member of an international scientific group dedicated advancing an understanding of the clearance of dying cells. He has organized three of the group’s biennial meetings, which are held in various locations, including the Gordon Conferences.
Since 2015, following a sabbatical at the Weizmann Institute in the peripheral nerve laboratory of Prof. Ori Peles, he has studied the pathogenesis and treatment of congenital CD59 (Blood 2013, Ann Neurol 2016) germline mutations, and more recently congenital CD55 germline mutation (N Eng. J Med 2017). This research is now focused on understanding physiology and pathophysiology of humans via naturally occurring monogenic germline mutations that causes autoimmune and autoinflammatory diseases.
Prof Mevorach has published over 100 scientific articles, including seminal papers on topics related to cell death and complement regulation as well as patent applications related to apoptotic cell-based therapies. He has mentored over 30 students conducting basic and translational research for completion of studies at the MD, MSc, and PhD levels, and as Department Chairman guides young physicians during their residencies in Internal Medicine. For the Hebrew University Faculty of Medicine, he has led changes from a traditional sequence of preclinical studies followed by clinical clerkships to an advanced integrated medical curriculum that simultaneously integrates greater depth in teaching the basic sciences as well as early student integration into the full range of clinical settings, with increased focus on research, communication skills and the medical humanities.

MD Camille L. Bedrosian

Alexion Pharmaceuticals

Lecture: Complement and Refractory Generalized Myasthenia Gravis

Sunday 10th

Biographic sketch

Camille L. Bedrosian, MD is Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals, Inc. A medical oncologist and hematologist, she brings more than 25 years of academic medical practice, research and drug development expertise to this role. At Alexion, she has provided leadership for the development of drugs and drug candidates across therapeutic areas encompassing complement-mediated diseases, including for Alexion's marketed terminal complement inhibitor, eculizumab, as well as more recently, therapeutics in the metabolic disease area.

Previously, Dr. Bedrosian spent more than five years as the Chief Medical Officer for ARIAD Pharmaceuticals, Inc., a small biotech company which specializes in discovery and development of small molecules to treat cancer by regulating cell signaling. Before joining ARIAD, Dr. Bedrosian served in the Clinical Research and Development Department of Genetics Institute, Inc., which was acquired by Wyeth, now part of Pfizer, and assumed roles of increasing responsibility, ultimately as Senior Director of Oncology/Hematology and Therapeutic Area Head for Hemophilia.

Dr. Bedrosian was an Assistant Professor of Medicine at Duke University Medical Center and member of the Duke Comprehensive Cancer Center, where she also had completed her residency in internal medicine and then fellowship in hematology and medical oncology.

Dr. Bedrosian is the author of numerous research publications, patents, presentations, and abstracts, and is a member of several professional associations. She also is a frequent invited external manuscript reviewer for several professional journals.

Dr. Bedrosian holds a B.A. degree in Honors Chemistry from Harvard University, an M.D. degree from Harvard Medical School and an M.S. degree in Biophysics from the Massachusetts Institute of Technology. She currently serves as Member of the MIT Corporation Visiting Committee for the Department of Biology.

Contact our congress agency